Market Closed -
London S.E.
14:50:38 04/02/2021 GMT
|
5-day change
|
1st Jan Change
|
13.97
USD
|
-0.43%
|
|
+800.77%
|
+25.84%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
177.7
|
434.2
|
436.8
|
197.5
|
593.2
|
76.63
|
-
|
-
|
Enterprise Value (EV)
1 |
177.7
|
294.3
|
354.7
|
58.82
|
670.5
|
-50.82
|
22.1
|
76.63
|
P/E ratio
|
-2.18
x
|
-4.36
x
|
-4.42
x
|
-7.8
x
|
-4.13
x
|
-0.71
x
|
-1.34
x
|
-5.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
253
x
|
28.5
x
|
7.75
x
|
19.1
x
|
1.95
x
|
1.32
x
|
0.68
x
|
EV / Revenue
|
-
|
171
x
|
23.1
x
|
2.31
x
|
21.6
x
|
-1.29
x
|
0.38
x
|
0.68
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-3.63
x
|
-4.83
x
|
-6.27
x
|
-0.51
x
|
-5.68
x
|
0.51
x
|
-0.37
x
|
2.13
x
|
FCF Yield
|
-27.6%
|
-20.7%
|
-16%
|
-195%
|
-17.6%
|
196%
|
-269%
|
47%
|
Price to Book
|
-
|
3.25
x
|
8.14
x
|
1.34
x
|
35.4
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
20,568
|
35,594
|
36,766
|
49,618
|
54,574
|
54,934
|
-
|
-
|
Reference price
2 |
8.640
|
12.20
|
11.88
|
3.980
|
10.87
|
1.395
|
1.395
|
1.395
|
Announcement Date
|
16/03/20
|
09/03/21
|
21/03/22
|
09/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.718
|
15.34
|
25.48
|
30.99
|
39.35
|
58.17
|
113
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-54.42
|
-67.94
|
-95.45
|
-112.8
|
-131.5
|
-106.7
|
-64.62
|
-28.57
|
Operating Margin
|
-
|
-3,954.42%
|
-622.05%
|
-442.69%
|
-424.3%
|
-271.15%
|
-111.09%
|
-25.29%
|
Earnings before Tax (EBT)
1 |
-54.12
|
-67.48
|
-98.78
|
-16.43
|
-142.9
|
-117.9
|
-76.01
|
-32.79
|
Net income
1 |
-54.12
|
-76.36
|
-98.78
|
-19.82
|
-141.4
|
-119.4
|
-78.66
|
-28.55
|
Net margin
|
-
|
-4,444.41%
|
-643.7%
|
-77.78%
|
-456.31%
|
-303.39%
|
-135.23%
|
-25.27%
|
EPS
2 |
-3.960
|
-2.800
|
-2.690
|
-0.5100
|
-2.630
|
-1.978
|
-1.038
|
-0.2717
|
Free Cash Flow
1 |
-49.02
|
-60.91
|
-56.57
|
-114.7
|
-118.1
|
-99.79
|
-59.46
|
36
|
FCF margin
|
-
|
-3,545.52%
|
-368.67%
|
-450.04%
|
-381.17%
|
-253.57%
|
-102.22%
|
31.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
09/03/21
|
21/03/22
|
09/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.52
|
14.19
|
1.79
|
2.34
|
7.162
|
10.38
|
6.081
|
7.338
|
7.19
|
7.679
|
9.507
|
10.23
|
11.93
|
10.99
|
12.32
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-27.12
|
-16.71
|
-36.77
|
-30.1
|
-29.21
|
-32.96
|
-31.44
|
-31.65
|
-35.44
|
-35.82
|
-30.58
|
-21.71
|
-18.63
|
-18.85
|
-17.03
|
Operating Margin
|
-1,783.95%
|
-117.8%
|
-2,053.97%
|
-1,286.28%
|
-407.87%
|
-317.56%
|
-517%
|
-431.26%
|
-492.87%
|
-466.48%
|
-321.62%
|
-212.2%
|
-156.16%
|
-171.51%
|
-138.28%
|
Earnings before Tax (EBT)
1 |
-28.3
|
-19.36
|
-39.43
|
75.04
|
-32.68
|
-34.73
|
-33.47
|
-32.97
|
-41.77
|
-38.67
|
-33.56
|
-24.45
|
-21.21
|
-20.5
|
-18.98
|
Net income
1 |
-28.3
|
-19.36
|
-39.43
|
71.63
|
-34.31
|
-34.73
|
-31.93
|
-32.97
|
-41.77
|
-38.67
|
-33.55
|
-24.09
|
-19.56
|
-20.5
|
-18.98
|
Net margin
|
-1,862.17%
|
-136.48%
|
-2,202.96%
|
3,061.28%
|
-479.08%
|
-334.59%
|
-525.14%
|
-449.33%
|
-580.93%
|
-503.57%
|
-352.88%
|
-235.5%
|
-163.97%
|
-186.58%
|
-154.1%
|
EPS
2 |
-0.7700
|
-0.5200
|
-1.060
|
1.890
|
-0.7600
|
-0.6700
|
-0.6100
|
-0.6100
|
-0.7400
|
-0.6800
|
-0.5940
|
-0.4510
|
-0.3160
|
-0.2483
|
-0.2300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/03/22
|
12/05/22
|
11/08/22
|
07/11/22
|
09/03/23
|
11/05/23
|
10/08/23
|
07/11/23
|
05/03/24
|
08/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
77.3
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
140
|
82.1
|
139
|
-
|
127
|
54.5
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-49
|
-60.9
|
-56.6
|
-115
|
-118
|
-99.8
|
-59.5
|
36
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
3.750
|
1.460
|
2.970
|
0.3100
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.39
|
-
|
1.1
|
1.77
|
0.11
|
-
|
1
|
1
|
Capex / Sales
|
-
|
-
|
7.14%
|
6.96%
|
0.35%
|
-
|
1.72%
|
0.89%
|
Announcement Date
|
16/03/20
|
09/03/21
|
21/03/22
|
09/03/23
|
05/03/24
|
-
|
-
|
-
|
Last Close Price
1.395
USD Average target price
6.667
USD Spread / Average Target +377.90% Consensus |
1st Jan change
|
Capi.
|
---|
| +52.93% | 803B | | +40.98% | 629B | | -7.08% | 351B | | +17.40% | 324B | | +10.58% | 303B | | +16.42% | 244B | | +2.17% | 226B | | +10.66% | 215B | | +6.24% | 164B |
Other Pharmaceuticals
|